HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Paul P Tak Selected Research

Rheumatoid Arthritis

1/2016	MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study.
12/2015	Epigenetic mechanisms and drug discovery in rheumatology.
12/2015	Prevalence of Anti-Citrullinated Protein Antibodies and IgM Rheumatoid Factor in First-Degree Relatives of Dutch Rheumatoid Arthritis Patients.
9/2015	JNK-dependent downregulation of FoxO1 is required to promote the survival of fibroblast-like synoviocytes in rheumatoid arthritis.
9/2015	Nuclear Factor-κB-inducing Kinase Is Expressed in Synovial Endothelial Cells in Patients with Early Arthritis and Correlates with Markers of Inflammation: A Prospective Cohort Study.
7/2015	Tertiary Lymphoid Structures in Rheumatoid Arthritis: NF-κB-Inducing Kinase-Positive Endothelial Cells as Central Players.
6/2015	MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial.
3/2015	MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis.
1/2015	Preclinical Potency and Biodistribution Studies of an AAV 5 Vector Expressing Human Interferon-β (ART-I02) for Local Treatment of Patients with Rheumatoid Arthritis.
10/2014	Citrullination of epithelial neutrophil-activating peptide 78/CXCL5 results in conversion from a non-monocyte-recruiting chemokine to a monocyte-recruiting chemokine.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research network!

Paul P Tak Research Topics

Disease

106	Rheumatoid Arthritis 01/2016 - 01/2002
51	Inflammation 01/2016 - 02/2002
38	Arthritis (Polyarthritis) 09/2015 - 10/2002
14	Experimental Arthritis 01/2015 - 01/2004
11	Synovitis 01/2016 - 08/2006
11	Psoriatic Arthritis 02/2014 - 10/2002
8	Necrosis 09/2015 - 01/2004
8	Osteoarthritis 10/2014 - 01/2004
8	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2012 - 01/2004
7	Autoimmune Diseases (Autoimmune Disease) 07/2012 - 01/2009
6	Spondylarthritis (Spinal Arthritis) 10/2012 - 06/2006
5	Systemic Lupus Erythematosus (Libman-Sacks Disease) 07/2013 - 03/2010
4	Rheumatic Diseases (Rheumatism) 10/2014 - 12/2008
4	Neoplasms (Cancer) 06/2009 - 03/2007
3	Osteitis 01/2016 - 04/2011
3	Melanoma (Melanoma, Malignant) 01/2012 - 01/2009
3	Juvenile Rheumatoid Arthritis (Juvenile Idiopathic Arthritis) 04/2011 - 04/2002
2	Bone Resorption 01/2014 - 03/2008
2	Joint Diseases (Joint Disease) 10/2013 - 06/2002
2	Pain (Aches) 03/2013 - 01/2010
2	Atherosclerosis 03/2012 - 03/2007
2	Infection 06/2011 - 01/2010
2	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 10/2010 - 01/2010
2	Asthma (Bronchial Asthma) 03/2010 - 01/2008
2	Hypersensitivity (Allergy) 01/2010 - 03/2006
2	Hyperplasia 08/2006 - 06/2006
1	Giant Lymph Node Hyperplasia (Castleman's Disease) 01/2015
1	Pathologic Constriction (Stenosis) 01/2015

Drug/Important Bio-Agent (IBA)

18	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2013 - 03/2005
14	rituximab (Mabthera)FDA Link 01/2016 - 03/2007
13	AntibodiesIBA 12/2015 - 11/2004
13	Biological Markers (Surrogate Marker)IBA 03/2012 - 12/2004
11	Methotrexate (Mexate)FDA LinkGeneric 01/2016 - 02/2002
11	Proteins (Proteins, Gene)IBA 12/2015 - 11/2004
9	CytokinesIBA 01/2014 - 06/2002
9	infliximab (Remicade)FDA Link 08/2011 - 01/2004
7	ChemokinesIBA 10/2014 - 01/2005
6	Rheumatoid FactorIBA 12/2015 - 11/2005
6	Antirheumatic Agents (DMARD)IBA 01/2014 - 06/2008
5	LigandsIBA 01/2015 - 12/2008
5	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA 01/2015 - 01/2009
5	Interleukin-17 (Interleukin 27)IBA 01/2014 - 01/2009
5	Interleukin-10 (Interleukin 10)IBA 01/2014 - 01/2006
5	Interleukin-6 (Interleukin 6)IBA 01/2014 - 01/2004
5	GTP Phosphohydrolases (GTPases)IBA 01/2012 - 01/2009
4	Immunoglobulin M (IgM)IBA 12/2015 - 08/2011
4	C-Reactive ProteinIBA 09/2015 - 01/2010
4	Phosphotransferases (Kinase)IBA 09/2015 - 05/2006
4	Interferon-betaIBA 01/2015 - 01/2002
4	tocilizumab FDA Link 01/2015 - 01/2011
4	TNFR-Fc fusion protein (etanercept)FDA Link 01/2013 - 03/2005
4	AntigensIBA 01/2012 - 01/2006
4	NF-kappa B (NF-kB)IBA 06/2009 - 01/2004
3	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 06/2015 - 01/2004
3	CollagenIBA 01/2015 - 04/2010
3	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 10/2014 - 08/2006
3	adalimumab (Humira)FDA Link 11/2013 - 01/2010
3	abatacept (BELATACEPT)FDA Link 08/2013 - 01/2011
3	Immunoglobulins (Immunoglobulin)IBA 06/2013 - 06/2011
3	Histone Deacetylase InhibitorsIBA 03/2012 - 03/2010
3	alefacept (Amevive)FDA Link 01/2012 - 10/2002
3	alpha7 nicotinic acetylcholine receptorIBA 09/2010 - 04/2009
3	Collagen Type II (Type II Collagen)IBA 01/2010 - 01/2009
3	HLA-DRB1 antigen (HLA DRB1)IBA 07/2009 - 06/2003
2	Lipoproteins (Lipoprotein)IBA 11/2015 - 07/2013
2	Apolipoprotein A-I (Apolipoprotein A1)IBA 11/2015 - 01/2015
2	InterleukinsIBA 09/2015 - 02/2014
2	Transcription Factors (Transcription Factor)IBA 09/2015 - 09/2015
2	Acetylcholine (Acetylcholine Chloride)FDA Link 01/2015 - 04/2009
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2014 - 12/2013
2	TIE-2 Receptor (Receptor, TIE 2)IBA 01/2014 - 08/2012
2	AutoantibodiesIBA 10/2013 - 07/2012
2	acetyl 4-aminosalicylic acidIBA 04/2013 - 07/2009
2	Poly I-CIBA 03/2012 - 01/2012
2	mycophenolate mofetil (Cellcept)FDA LinkGeneric 03/2012 - 07/2010
2	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2012 - 12/2008
2	RNA (Ribonucleic Acid)IBA 01/2012 - 07/2009
2	ametantrone (HAQ)IBA 04/2011 - 12/2008
2	Interferon Type IIBA 12/2010 - 01/2010
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 11/2010 - 07/2009
2	Insulin (Novolin)FDA Link 06/2010 - 02/2005
2	Messenger RNA (mRNA)IBA 06/2010 - 11/2008
2	Histone Deacetylases (Histone Deacetylase)IBA 03/2010 - 01/2008
2	Neurotransmitter Agents (Neurotransmitter)IBA 05/2009 - 04/2009
2	Interferon-gamma (Interferon, gamma)IBA 04/2009 - 01/2009
2	leflunomide (Arava)FDA LinkGeneric 03/2009 - 02/2002
2	Matrix MetalloproteinasesIBA 01/2009 - 06/2006
2	Interleukin-7 (Interleukin 7)IBA 11/2008 - 08/2007
2	Interleukin-8 (Interleukin 8)IBA 04/2007 - 01/2004
2	Transforming Growth Factor beta (TGF-beta)IBA 03/2007 - 02/2005
2	I-kappa B KinaseIBA 08/2006 - 01/2006
2	Interleukin-18 (Interleukin 18)IBA 04/2006 - 06/2002
1	Agammaglobulinaemia tyrosine kinase (Bruton's tyrosine kinase)IBA 08/2015
1	LeptinIBA 01/2015
1	DNA (Deoxyribonucleic Acid)IBA 01/2015
1	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 01/2015
1	AdiponectinIBA 01/2015
1	FibrinIBA 01/2015

Therapy/Procedure

4	Aftercare (After-Treatment) 01/2012 - 03/2005
3	Biological Therapy 01/2016 - 06/2011